Sign up for our FREE Spine E-Weekly for more coverage like this sent to your inbox!
Alphatec Spine (Down 5.2 percent). Alphatec Spine announced second quarter net revenue of $48.2 million, a 5.2 percent decrease over the same period last year. United States revenues were down from $34.5 million last year to $32.6 million this year. However, the company reported strong sales of its new anterior cervical plate, Trestle Luxe, and biologics products.
Biomet Spine (Up 5 percent). Biomet reported net sales of $739.5 million in the fourth quarter of the 2012 fiscal year, a 3 percent increase over last year. The company’s spine and bone healing business grew 5 percent to $83.9 million. For the year’s end, the large joint reconstructive business reached $1.6 billion, but the spine and bone healing products dropped 4 percent overall. The company reported $229.2 million in adjusted operating income and an operating loss of $378 million during the forth quarter. This is significantly less than the operating loss from the same period last year, reported at $847.3 million. The company’s large joint reconstructive business grew 3 percent and the sports, extremities and trauma grew 14 percent to $96.2 million.
Exactech (Down 1 percent). Exactech reported revenue of $55.2 million for the second quarter, a 7 percent increase over the same period last year. The company reported a 1 percent decrease in its biologic and spine business. The company’s revenue from knee implants increased 1 percent and revenue from hip implants increased 22 percent. United States sales increased 8 percent to $35.2 million. The company outperformed expectations, according to chairman and CEO Bill Petty.
Integra LifeSciences (Up 4 percent). Integra LifeSciences reported $210.2 million revenue for 2Q, a 9 percent increase over the same period last year. The company’s United States spine business reported a 4 percent decrease over the same period last year, reaching only $45.7 million. The United States orthopedics business grew 22 percent to $80.7 million but dropped 2 percent internationally. The company’s U.S. neurosurgery market grew only 2 percent while the international market dropped 5 percent for a worldwide neurosurgery market decrease by 1 percent to $67.7 million.
NuVasive (Up 16.1 percent). Spine device company NuVasive reported $154.4 million in revenue during the second quarter, up 16.1 percent over the same period last year. The second quarter report showed gross profit of $117.9 million and gross margin of 76.3 percent. However, the company reported higher operating expenses during the second quarter, reaching $104.9 million, due to costs associated with higher revenue and infrastructure expansion. The company reported around $253,000 in net loss attributable to non-controlling interests.
Orthofix Spine (Up 7 percent). Orthofix reported $119.5 million in net sales for the second quarter, a 2 percent increase over the same period last year. The company’s total spine business grew 7 percent over the same period last year, generating $81.8 million in net sales for the second quarter. The company reported net income at $14 million, up from $10.5 million over the same period last year. Its spine business reported $81.8 million in net sales, a 7 percent growth, while the orthopedics business dropping 6 percent to $37.7 million. Throughout the second quarter, the company saw increased use of the Trinity Evolution in spine applications, which led to a 48 percent increase in sales for the regenerative biologics business.
Stryker Spine (Up 12 percent). Stryker reported $325 million profit for the second quarter of 2012, a 4.6 percent increase over the same period last year. The company’s neurology and spine business lines saw the greatest growth, a 12 percent increase over the previous year. The company also reported a 2.9 percent net sales increase to $2.1 billion. United States sales showed a 7.7 percent increase to $1.3 billion, while international sales declined 5.1 percent to $722 million. Knee sales grew 2.6 percent while hip sales were up 1 percent.
Zimmer Spine (Down 7 percent). Zimmer reported $1.1 billion in net sales for the second quarter, a 1.1 percent decrease over the same period last year. The company’s reconstructive business reached $843 million in net sales, down 2 percent, and the spine business was down 7 percent. However, the company’s trauma business rose 7 percent. Sales in the American market grew 1 percent to $614 million. Hip sales in the American market remained flat while knee sales declined 1 percent.
More Articles on Orthopedic Devices:
40 Orthopedic & Spine FDA 510(k) Device Clearances in July
Lanx Announces Patent Grant for ASPEN MIS Fusion System
Misonix Adds 6 Spine Sales Agencies
